21 – 30 of 117
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality : 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial
- Contribution to journal › Article
-
Mark
Smoking and Risk of Prostate Cancer and Prostate Cancer Death : A Pooled Study
- Contribution to journal › Article
-
Mark
Long-term Risks of Depression and Suicide Among Men with Prostate Cancer : A National Cohort Study
- Contribution to journal › Article
-
Mark
Re: Mark N. Brook, Holly Ní Raghallaigh, Koveela Govindasami, et al. Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study. Eur Urol 2023;83:257-66
- Contribution to journal › Letter
-
Mark
Re : Alexander Cox, Niklas Klümper, Johannes Stein, et al. Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.03.020
- Contribution to journal › Letter
-
Mark
European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022 : The Urologist's Point of View
- Contribution to journal › Debate/Note/Editorial
-
Mark
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma : 2023 Update
- Contribution to journal › Scientific review
-
Mark
The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma
- Contribution to journal › Article
-
Mark
Re : Laura S. Mertens, Richard P. Meijer, J. Alfred Witjes. Positron Emission Tomography/Computed Tomography for Staging of Bladder Cancer: A Continuing Clinical Controversy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.017
- Contribution to journal › Letter
-
Mark
Re : Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate Cancer
- Contribution to journal › Debate/Note/Editorial
